TheEdgeResearch
Home / Stocks / MDWD

MediWound Ltd. (MDWD)

NASDAQ Healthcare Biotechnology
$13.59 ▲ +0.37%
Market Cap
$175.5M
Sector
Healthcare
Industry
Biotechnology
Beta
0.14
52-Wk Range
11.8-19.7
CEO
Ofer Gonen
Country
IL
Currency
USD

MediWound Ltd. operates in the Biotechnology industry of the Healthcare sector, headquartered in Yavne, HM, IL. The stock last traded at $13.59, up 0.37% on the session, giving a market capitalisation of $175.5M. On trailing twelve-month figures it carries a trailing P/E of -7.47, a net margin of -235.0%. Its beta of 0.14 implies it has historically moved less than the broad market.

Valuation & profitability (TTM)
P/E
-7.47
Price / Sales
17.53
Price / Book
5.54
EV / EBITDA
-6.24
Gross margin
19.5%
Operating margin
-337.8%
Net margin
-235.0%
Return on equity
—
Debt / equity
0.26
Current ratio
2.23
Dividend yield
0.0%
Payout ratio
0.0%
Company profile
Exchange
NASDAQ
Employees
121
IPO date
2014-03-20
Headquarters
Yavne, HM, IL
About MediWound Ltd.

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in the United States, Germany, Italy, Spain, and internationally. The company markets NexoBrid, a biopharmaceutical product for the removal of eschar in patients with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. It also develops EscharEx, a bromelain-based, bioactive enzymatic therapy for the treatment of chronic wounds and other hard-to-heal wounds; and MW005, a topically applied biological product candidate to treat non-melanoma skin cancers. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.

Comparable companies

MediWound Ltd. is most often compared with the following Healthcare names:

AARDEPRXGNFTIVAIVVDNTHIOBIORNACSLSTARA
More research on MDWD
MDWD technical analysis MDWD TheEdge Score Compare against peers
Open full interactive analysis & DCF →